As the public's interest in genetics and genomics has increased, there has been corresponding and unprecedented growth in direct-to-consumer genetic testing (DTC-GT). Although regulatory concerns have limited true DTC-GT available without a physician order, the paradigm has shifted to a model of consumer-directed genetic testing (CD-GT) in which patients are researching testing options and requesting specific genetic testing from their health-care providers. However, many nongenetics health-care providers do not have the background, education, interest, or time to order and/or interpret typical clinical genetic testing, let alone DTC-GT. The lines between CD-GT, DTC-GT, and traditional clinical genetic testing are also blurring with the same types of tests available in different settings (e.g., carrier screening) and tests merging medical and nonmedical results, increasing the complexity for consumer decision-making and clinician management. The genetics community has the training to work with CD-GT, but there has been a hesitancy to commit to working with these results and questions about what to do when consumers have more complicated asks, like interpretation of raw data. Additionally, at the rate with which CD-GT is growing, there are questions about having sufficient genetics professionals to meet the potential genetic counseling demand. While there are many complex questions and challenges, this market represents a chance for the genetics community to address and unmet need. We will review the history of the CD-GT/DTC-GT market and outline the issues and opportunities our profession is facing.
2011, New York Times columnist, Paul Krugman, authored an opinion piece quite bluntly called, "Patients are not Consumers. " Krugman (2011) identifies multiple concerns including medical ethics and the sanctity of patient-physician relationship, and at the core of his argument he laments, "there's something terribly wrong with the whole notion of patients as 'consumers' and health care as simply a financial transaction." The opposing viewpoint is one that places the individual as a partner in health care. One who warrants "the transparent, actionable information they need to make smart choices about their care" (Greenberg & Tavenner, 2016) and where "the ideal patient experience merges excellent medical care, high-quality outcomes, compassion, and empathy that address the emotional needs of patients" (Rosen, 2016) .
In the context of this article, the authors find that "consumer" is the most appropriate term as it broadly encompasses all who are exposed to and pursue these testing services.
This terminology seems additionally apt given the direction of marketing and sales of genetics tests via retail stores, both "brick-andmortar" and online. Within a 4-day timespan ("Black Friday" through "Cyber Monday," November 2017), Ancestry.com sold an estimated 1.5 million DNA kits, a threefold increase compared to the same period in 2016 (Molteni, 2017) . During that same time, 23andMe's Ancestry test was one of the top five sellers on Amazon.com (Molteni, 2017) .
Given the degree of expansion that genetic testing has achieved in the consumer market, the consumer mindset is of particular importance.
A recent article in Lifehacker generated an example of how these lines are blurred in the mind of consumers which then provoked an intriguing conversation on Twitter about the issue. In November 2017, in the context of the holiday shopping season, "What You Should Know Before You Gift Someone a DNA Test," discussed some of the privacy and ethical issues that are not always considered by the average consumer. In the comments, a reader stated, "Bought the $99 one from amazon [sic] the other day from 23andme [sic] . Ancestry and genetic carrier testing.
We are planning on trying to have a baby in the spring, and this is a hell of a lot cheaper than the testing through the MD" (snowchi99, 2017). A geneticist shared this comment on Twitter with a horrified tweet, "Oh god, no. People, I have a PhD in genetics and I still went to a genetic counselor for my pregnancy. Personal ancestry tests are NOT a substitute for medical experts" (Raff, 2017) . The subsequent discussion in response to the tweet was wide-ranging and included comments about DTC companies making genetic testing more accessible when cost is a concern, situations where the consumer knew more than their providers about the results and the test and examples of how genetic counselors found issues in the family history that "routine" testing would not have identified.
While we health-care providers might like to think that these tests are far off from our day-to-day clinical practices, recent surges in interest indicate that it is not. As the often-quoted William Gibson said, "The future is already here-it's just not very evenly distributed."
| CD -GT: D EF I NI TI ON S
To put some clarity into the haziness of this space, it is important to define some of the terms that are being used. Although these definitions may not be consistently used in the same ways, particularly between professional and lay audiences, they help to define the scope of this area. Specific examples of consumer-directed testing, including ancestry studies, clinical genetic testing, and nonmedical genetic studies are provided in Table 1 . The example of 23andMe demonstrates how a single test can cross over several of these categories, adding to the complexity of describing and understanding the boundaries of testing.
CD-GT (also referred to as patient directed, patient initiated, consumer initiated, or similar): The practice of selling or marketing genetic testing directly to an individual rather than to their treating health-care providers. While some tests may still require that their (2006) commented, "By advertising BRACAnalysis to the general public, Myriad is deploying a technology that is speculative at best, exploiting a climate of genetic determinism and the public's misunderstandings of and anxieties about susceptibility, probability and risk." The Centers for Disease Control (CDC) studied the pilot campaign and found consumers in Atlanta and Denver were more aware of BRCA1 and BRCA2 genetic testing compared with survey participants in two cities not exposed to the campaign. Health-care providers in the pilot cities reported more questions about and requests for BRCA1 and BRCA2 genetic testing and more tests ordered, but also reported lacking the knowledge to advise their patients about hereditary breast and ovarian cancer syndrome or the appropriateness of testing (CDC, 2004) . A cancer genetics center in the campaign area assessed their referral data, as well as the number of patients identified as "high risk" after genetic counseling/ risk assessment. They found a 244% increase in referrals from the previous year and a drop in patients considered to be "high-risk" of having a BRCA1 or BRCA2 mutation from 69% to 48% (Mouchawar et al., 2005) .
The DTC marketing campaign, followed by Angelina Jolie's disclosure of her BRCA mutation status in the New York Times (Jolie, 2013) and the role that it played in her subsequent medical treatment plan (Jolie Pitt, 2015) , have led to an increased awareness and demand for BRCA1 and BRCA2 testing by consumers. There are concerns about undue psychological stress or worry because of the increased awareness (Lowery, Byers, Axell, Ku, & Jacobellis, 2008) or, even worse, cases of individuals getting inappropriate or the wrong medical care because testing was ordered and/or interpreted by a health-care provider who did not understand the genetic test results (Bever, 2017) . Ultimately, making consumers aware of the BRCA genes has led to women and men having discussions with family members about cancer, better educating themselves about their cancer risks, potentially leading to increased cancer screening, preventative measures, and/or earlier diagnoses, as appropriate. The awareness that BRCA1 and BRCA2 testing can have a dramatic impact on improving cancer screening and prevention prompted Dr. Mary-Claire King, who co-discovered BRCA1, to raise the idea of population based screening for BRCA1 and BRCA2
mutations (King, Levy-Lahad, & Lahad, 2014) .
Marketing genetic testing to consumers was met with concern by many in the genetics community (genetic counselors, medical geneticists, nurses with genetics training, etc.), but there was some reassurance that a health-care provider would still be involved in ordering the testing and managing the results with the corresponding duty of care.
In 2008, 23andMe took consumer-directed testing to a new level. Co- (Evenson, Hoyme, Haugen-Rogers, Larson, & Puumala, 2016) . This raised the question of whether CD-GT may lead to over-or under-screening or mismanagement of individuals. Powell et al. (2012) found that 43% of physicians who were aware of DTC-GT thought that testing was clinically useful to formulate a medical management plan, even though there was no data to support this.
| T HE R EGU L A TOR Y L AN D SCA P E
Following the wide launch of 23andMe's genetic testing offering in 2008, several other companies marketed similar tests, generally featuring a mix of nonmedical and medical testing (as defined above). As these companies became more prevalent, the scrutiny of the FDA and other regulatory agencies grew tighter.
However, investigations of DTC genetics companies preceded even 23andMe's Time magazine accolades. In 2006, the United States Government Accountability Office (GAO) published an investigation of companies offering DTC nutrigenetic testing, defined in the study as "tests [that] purport to analyze a limited number of genes to provide personalized nutritional and lifestyle recommendations," finding that they "mislead consumers" (Kutz, 2006) . The GAO subsequently started an investigation of four DTC genetic testing companies that were prominent at the time, assessing the reliability of DTC results for medical claims along with assessments of "supplement sales, test reliability, and privacy policies" (Kutz, 2010) . specifically as a 'first step in prevention' that enables users to 'take steps toward mitigating serious diseases' such as diabetes, coronary heart disease, and breast cancer" (Gutierrez, 2013) . While the letter to 23andMe was the most visible, several other companies received similar warnings and all were instructed that corrective action was required and that they must follow a regulated path to offer testing or cease operations. As noted earlier, 23andMe was the only company that has pursued an FDA-cleared path to offer DTC testing to date.
| TH E IM P A CT TO D A TE
While regulatory bodies continue to evaluate where and when they have authority to oversee CD-GT/DTC-GT, concerns about testing analytics, clinical utility and both consumer and clinician understanding of this type of testing led to multiple professional organization and panels issuing policy or guidance statements about CD-GT/DTC-GT. Initially, many of these statements addressed issues regarding the:
certifications of the labs performing the tests, evidence used to determine which genes or single nucleotide variants (SNVs) to include, lack of evidence-based guidelines for managing results, lack of federal oversight, privacy of genetic test results and consumer data, and potential psychological risks to consumers of CD-GT/DTC-GT (American College vider. This often led to additional health screenings or follow-up tests, but it is not clear whether these tests were needed or appropriate (Stewart et al., 2018) . These results, while cautiously reassuring that a significant number of people are not experiencing emotional or healthrelated harm from CD-GT/DTC-GT, have mostly been conducted on European Americans who are highly educated and have high income levels. As a result, it is not certain whether these results are generalizable to other consumers undergoing CD-GT/DTC-GT.
An emerging issue is that of raw data analysis and the subsequent impact on clinical care. As detailed by Kirkpatrick and Rashkin, ancestry providers are providing access to the raw data files containing the variant calls from the consumer testing. While these files are flagged as intended for research use only by the testing companies, it highlights another growing area of interest for "citizen scientists" who want to dig into their own data with third-party analysis software (Kirkpatrick & Rashkin, 2017 were not confirmed by the laboratory and of those that were, seven of variants suspected to cause "increased risk" were determined to be polymorphisms by the clinical laboratory (Tandy-Connor et al., 2017) .
While additional detail about the origins of these discrepancies is needed, it suggests that both variants called by the DTC laboratories and the interpretations provided by third-party raw data interpretation tools must be questioned. More importantly, consumers and healthcare providers must be aware of the false-positives that are seen in raw data and recognize that any result stemming from raw data analysis be confirmed in a clinical laboratory before incorporating it into clinical care.
| M O V I NG I NTO DA Y LI GH T: CH A LL EN GE S A ND OP P OR TU NI T IE S F OR GE NE TI CS PR OF ESSION A LS
Given all the questions and concerns raised surrounding CD-GT/DTC-GT, genetic counselors are aptly suited to support both consumers and health-care providers in navigating CD-GT/DTC-GT testing. pursued DTC-GT (Hock et al., 2011) .
Companies are providing services across a broad range of consumer-directed testing categories (Table 1) "interpretation." Having an understanding of these concepts and tools will ready genetics providers to interpret CD-GT/DTC-GT results as well as assess the accuracy of results, especially for consumers who review their raw data file or run it through third-party software. As an example, Family Tree DNA removes some health-related SNVs before providing the raw data file to a consumer (Kirkpatrick & Rashkin, 2017 ). This would obviously have an impact on the information a consumer might receive and thereby impact the counseling a genetics provider would need to provide to their patient. Therefore, it is up to the genetics societies like ACMG and NSGC and training programs to educate members and students about these tests and tools, as they do for clinical genetic tests, to prepare them for counseling patients who present with CD-GT/DTC-GT results. To address workforce issues until there are more trained providers, new service delivery models are being employed (Cohen et al., 2013) . In addition to the traditional "brick-and-mortar" in-person genetic counseling services, the virtual health genetics space has been expanding with more hospitals starting to offer this service and the launch of several new companies that provide on-demand access to a virtual genetics Another critical piece to this discussion is the cost of genetic counseling and who will pay for the consultation. Despite the benefits of genetic counseling, reimbursement for genetics services remains limited, depending on whether a consultation is being billed under a health-care provider or a genetic counselor. This is primarily because licensed genetic counselors cannot be paid by the Center for Medicare and Medicaid Services (CMS) because they are not currently recognized as independent nonphysician providers. Outside of the CMS system, genetic counselors can only bill directly for their services using CPT code 96040 (Beebe, Dalton, Espronceda, Evans, & Glenn, 2006) , and this applies only in some settings. Reimbursement for this code is minimal and private payers vary in their coverage.
One study showed that almost 63% of encounters billed to private payers using code 96040 received some reimbursement (Gustafson, Pfeiffer, & Eng, 2011) 
| C ONC LUSI ON
The landscape of CD-GT/DTC-GT is complex, with a lack of consensus on everything from definitions to regulation to counseling approaches.
The exception is in the dramatic uptake of testing that has occurred in the past 10 years. As CD-GT/DTC-GT companies are helping to drive demand, one could argue that they have a responsibility to help their customers interpret and understand the results, either through direct services or referrals. While genetics providers may disagree on the approach or strategy, we must accept that this type of testing is going to be a part of our practices in some form and maintain an open dialog across specialties. Collaboration with the CD-GT/DTC-GT companies, consumers and nongenetics health-care providers must all be evaluated as responsible and quality solutions are needed for the many open issues surrounding this urgent issue. 
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